At the news
? BULLISHIMPACT 7/10 8-K filed Aug 10, 2026 at 07:57 ET
Silence Therapeutics announced positive topline Phase 2 SANRECO trial results for divesiran in polycythemia vera (PV). The primary endpoint was met with a significantly higher proportion of clinical responders (88% vs 19% placebo; p<0.0001), and both Q6W and Q12W dosing showed strong efficacy (93.8% and 81.3% response rates, respectively). The company plans to initiate a Phase 3 trial in 1H 2027, supporting divesiran's potential as a best-in-class siRNA therapy for PV.
- Primary endpoint met: 88% clinical responders for divesiran vs 19% placebo (p<0.0001), placebo-adjusted response rate 69%.
- Dose groups: 93.8% response at Q6W and 81.3% at Q12W.
- Key secondary endpoint: mean phlebotomies reduced to 0.2 (divesiran) vs 2.1 (placebo) during weeks 0-36 (p<0.0001).
- Safety well-tolerated with no new findings; injection site reactions infrequent and self-limiting.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access